Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. (Q34522522)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

author name string

Taha H Taher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Vladimir Dzavik

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Ethel M Reteff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Bonnie L Woloschuk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Gordon A Francis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

language of work or name

English

0 references

publication date

1 February 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

390-394

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902258-5

10.1016/S0002-9149(01)02258-5

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11835917%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference